Journal: medRxiv
Article Title: A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy
doi: 10.64898/2026.01.21.26344562
Figure Lengend Snippet: Impact of BYL-719 on the expression of target proteins in cervical cancer cell lines. (A, B) CaSki cells treated with BYL-719 show reduced levels of PD-L1, YAP1, EGFR, CTGF, Integrin, and HPV16 E7. In Panel B cells were treated with 5 uM BYL-719, washed at 24h and place in 0, 1 or 5 uM drug. (exposure time, 2 min). (C) BYL-719-treated ME180 cells show decreased levels of PD-L1 and CTGF. (D) SNU-17 cells also show reduced levels of these proteins after treatment (exposure time, 5 min). (E) SiHa (PIK3CA wild-type) shows no reduction in PD-L1 or HPV16 E7 after treatment with BYL-719 (exposure time, 3 minutes). (F) Cell proliferation plot of SNU-17 cells treated with BYL-719 (G). SiHa cells treated with BYL719. *=P<0.05, **=P< 0.01, ***=P<0.001.
Article Snippet: CC cell lines, including CaSki (ATCC Cat# CRM-CRL-1550_Ca Ski, RRID: CVCL_1100), SiHa (ATCC Cat# HTB-35_SiHa, RRID: CVCL_0032 and ME180 (ATCC Cat# HTB-33_ME-180, RRID: CVCL_1401), C33A (ATCC CRM-HTB-31, RRID:CVCL_1094) were obtained from ATCC.
Techniques: Expressing